Trials ongoing and planned as can be found listed online at the Clinical Trials Register.

Dupuytren’s

In Oxford and Edinburgh, UK the RIDD trial has started in 2017 and has now stopped recruiting, as they have enrolled the number of patients needed. The trial is being continued in Groningen, the Netherlands. Patients with Dupuytren’s nodules who have not had any other treatment yet will be injected with a drug commonly used for Rheumatoid Arthritis or a placebo, to see if it stops the progression. More information on the trial can be found on our Research page. The drug (Adalimumab) is also being tested for Frozen Shoulder.

The DISC trial, Dupuytren’s Interventions: Surgery versus Collagenase, a multicentre randomised trial comparing Limited fasciectomy to collagenase, results and costs. The centra involved are Derby, Blackburn, Liverpool, Leicester, Southampton and Newcastle upon Tyne. They have now stopped recruiting.

Hand-2, a study starting soon to compare the longterm results of Limited Fasciectomy versus those of Percutaneous Needle Fasciotomy. Prof Tim Davis is the lead investigator, and the study will run in Nottingham and several other locations.

In Oslo a comparison between PNF and Collagenase, and 5-year follow up. They are no longer recruiting (Norway).

In Haukeland University Hospital in Norway a trial to determine whether physical therapy improves outcomes after collagenase for Dupuytren’s.

In Belgium, in the ‘Universitair Ziekenhuis Leuven’ a trial is starting led by Prof I Degreef, into the use of Vivisorb at the end of fasiectomy surgery, to see if it will act as functional firebreak and prevent contracture recurrence.

In Calgary, Canada a study comparing PNF with Collagenase injections, and especially the rate of recurrence up to 5 years.

In Ontario, Canada a trial comparing Collagenase with Limited Fasciectomy.

In Quebec,  Canada a trial is being held comparing the effectiveness of two post-fasciectomy rehabilitation protocols in patients with Dupuytren’s Disease. The aim is to evaluate if higher intensity therapy gives better results.

In the Mayo Clinic, Rochester, USA a trial is on the way investigating ‘The effects of Prophylactic Limited Palmar Fasciectomy on surgical outcome and scarring’ , where the theory that removing a thickened pretendinous cord that causes a Trigger Finger gives less complications afterwards than just cutting the cord as is done normally in a surgical procedure for Trigger Finger.

In Minneapolis, Minnesota a trial has started to discover the effect of radiotherapy on disease recurrence after surgical correction of contracture for Dupuytren’s. Dr Dusenbury is the main investigator in the trial.

A trial to monitor the results of radiation therapy for Dupuytren’s has started in Australia, with a possible international involvement in the future. It is known as DEPART  (Dupuytren’s disease: Evaluation of Preventative and Adjuvant Radio Therapy) The trial is run by Genesis Care and Hunter Hand Surgery at Lake Macquarie, Australia. Hand surgeon Dr Brett McClelland and Radiation Oncologist Dr Jarad Martin are the main doctors involved. The trial, which is run as a doubleblind, will evaluate the effect of radiation both in early stage Dupuytren’s and after treatment to correct contracture.

Ledderhose

In the Netherlands a double blind trial comparing the effects of radiation therapy for Ledderhose Disease has started in 2018, and has now closed to new patients. The centra involved are in Groningen, Arnhem, Amsterdam, Eindhoven and Delft. Patients have to be Dutch speaking and not had any treatment to that foot yet.

The trial information for patients can be found here: LedRad – Studie-pdf (leaflet in Dutch)

In Texas and Illinois, USA a small study using Collagenase (Xiaflex) in Ledderhose patients is starting in 2020.

Peyronie’s

In Miami, Florida USA a trial is about to start (Sept 2020) using PRP for Peyronie’s Disease.

In Assiut, Egypt a trial is due to start November 2017 comparing the outcome of different types of surgery for Peyronie’s.

In Odense, Denmark a trial using ESWT (shockwave) and vacuum devices for Peyronie’s

Dr R. Flannigan of British Columbia University is planning a trial using fractionated carbon dioxide laser for Peyronie’s.